EU committee gives nod to Gilead's Viread for hepatitis B

03/20/2008 | Reuters

Gilead's HIV/AIDS drug Viread has been recommended for approval to treat hepatitis B by the European Medicines Agency's Committee for Medicinal Products for Human Use. The company is also awaiting approval from the FDA.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY